Table 3. Specific Susceptibility Loci and GD Risk Loci Associated With TPP by 2-Stage GWAS.

Chr and SNP	BP	Annotated Genes	Alleles	TPP												Heterogeneity (TPP vs GD)
				GWAS (171 vs 2160)				Replication (362 vs 1089)				Combined (533 vs 3249)
				F_TPP	F_Cons	P Value	OR (95% CI)	F_TPP	F_Cons	P Value	OR (95% CI)	F_TPP	F_Cons	P Value	OR (95% CI)	F_TPP	F_GD	P Value	OR (95% CI)
4q31.3 rs1352714a	155243604	DCHS2	T/C	0.22	0.14	3.69 × 10−5	1.74 (1.33-2.27)	0.19	0.14	5.03 × 10−5	1.51 (1.24-1.84)	0.20	0.14	1.24 × 10−8	1.58 (1.35-1.85)	0.20	0.15	7.01 × 10−6	1.46 (1.24-1.72)
6p21.3 rs4947296b	31058178	C6orf15	C/T	0.27	0.15	1.99 × 10−8	2.07 (1.61-2.66)	0.25	0.14	1.38 × 10−13	2.05 (1.70-2.46)	0.26	0.14	3.08 × 10−22	2.06 (1.77-2.39)	0.26	0.21	.001	1.28 (1.11-1.48)
6p21.3 rs1521b	31350704	MICA/HLA-B	T/C	0.90	0.83	.001	1.80 (1.27-2.57)	0.92	0.79	4.36 × 10−16	3.04 (2.30-4.00)	0.91	0.81	3.63 × 10−18	2.51 (2.02-3.13)	0.91	0.88	.001	1.45 (1.16-1.81)
6p21.3 rs6457617b	32663851	HLA-DQB1 and HLA-DQA2	T/C	0.64	0.49	1.55 × 10−7	1.84 (1.47-2.31)	0.58	0.45	4.35 × 10−11	1.69 (1.44-1.97)	0.60	0.47	2.37 × 10−17	1.74 (1.53-1.97)	0.60	0.47	5.35 × 10−5	0.76 (0.67-0.87)
6p21.3 rs2281388b	33060118	HLA-DPB1 and COL11A2	A/G	0.48	0.33	3.80 × 10−8	1.82 (1.46-2.27)	0.46	0.33	4.00 × 10−12	1.71 (1.47-1.99)	0.46	0.33	2.46 × 10−18	1.74 (1.54-1.98)	0.46	0.44	.11	1.09 (0.96-1.24)
11q14.1 rs2186564a	77583266	C11orf67	A/G	0.25	0.16	2.40 × 10−5	1.75 (1.35-2.27)	0.22	0.17	.0008	1.37 (1.14-1.65)	0.23	0.17	2.80 × 10−7	1.50 (1.29-1.74)	0.23	0.18	.0005	1.32 (1.13-1.54)
17q24.3 rs623011a	68259446	KCNJ2 and CTD-2378E21.1	A/G	0.63	0.47	1.19 × 10−8	1.92 (1.53-2.41)	0.63	0.46	5.33 × 10−15	2.00 (1.69-2.38)	0.63	0.46	1.33 × 10−22	1.96 (1.72-2.24)	0.63	0.46	4.95 × 10−20	1.96 (1.70-2.26)
17q24.3 rs17714860a	68272354	KCNJ2 and CTD-2378E21.1	G/A	0.88	0.79	8.65 × 10−5	1.91 (1.37-2.66)	0.87	0.80	6.27 × 10−5	1.63 (1.28-2.07)	0.87	0.79	2.31 × 10−8	1.74 (1.44-2.10)	0.87	0.80	1.25 × 10−7	1.71 (1.40-2.08)
17q24.3 rs411079a	68291371	KCNJ2 and CTD-2378E21.1	C/A	0.76	0.67	.0005	1.56 (1.21-2.01)	0.77	0.67	2.11 × 10−7	1.71 (1.40-2.09)	0.77	0.67	1.26 × 10−10	1.64 (1.40-1.91)	0.77	0.67	5.24 × 10−11	1.69 (1.44-1.99)
17q24.3 rs312729a	68306837	KCNJ2 and CTD-2378E21.1	A/G	0.64	0.47	2.54 × 10−10	2.05 (1.63-2.57)	0.65	0.47	8.75 × 10−20	2.11 (1.79-2.48)	0.65	0.47	8.02 × 10−29	2.08 (1.83-2.38)	0.65	0.47	3.12 × 10−27	2.10 (1.84-2.40)
17q24.3 rs312691a	68326338	CTD-2378E21.1	C/T	0.64	0.46	1.49 × 10−10	2.06 (1.64-2.59)	0.63	0.46	1.31 × 10−14	1.99 (1.67-2.37)	0.63	0.46	6.08 × 10−24	2.02 (1.77-2.31)	0.63	0.45	7.02 × 10−24	2.08 (1.81-2.39)
17q24.3 rs12451295a	68376823	CTD-2378E21.1 and SOX9	C/T	0.63	0.50	3.36 × 10−6	1.70 (1.36-2.13)	0.6	0.48	1.32 × 10−8	1.63 (1.38-1.94)	0.61	0.49	2.41 × 10−13	1.61 (1.41-1.84)	0.61	0.48	3.91 × 10−12	1.64 (1.43-1.89)
17q24.3 rs16975792a	68433725	CTD-2378E21.1 and SOX9	G/A	0.67	0.57	.0004	1.51 (1.20-1.91)	0.66	0.57	2.42 × 10−5	1.46 (1.22-1.73)	0.66	0.57	4.04 × 10−8	1.46 (1.27-1.67)	0.66	0.56	2.81 × 10−8	1.50 (1.30-1.73)
Xq21.1 rs5912838b	78497118	ITM2A	A/C	0.68	0.58	.002	1.50 (1.10-2.07)	0.70	0.58	1.31 × 10−5	1.68 (1.36-2.07)	0.69	0.58	5.91 × 10−8	1.62 (1.36-1.93)	0.69	0.64	.44	1.25 (1.05-1.49)

Abbreviations: BP, base position; Chr, chromosome; Cons, controls; F, minor allele frequency; GD, Graves disease; GWAS, genome-wide association study; OR, odds ratio; SNP, single-nucleotide polymorphism; TPP, thyrotoxic periodic paralysis.

^aFor the specific SNPs associated with TPP, the heterogeneity analysis were performed in the total of 533 patients with TPP and 1404 patients with GD.

^bFor the 5 SNPs associated with GD in the previous study, the heterogeneity analysis was performed in the total of 533 patients with TPP and 5160 patients with GD.